Between 55% (in Germany) and 93% (in the United States) of PCPs have accessed the Internet, according to I.MD 2000, a global study conducted by Montreal-based P\S\L Research. Projections made based on stated future intentions indicate that by the second quarter of 2001, between 75% (in Germany and Italy) and 97% (in the United States) of primary care physicians will have accessed the Internet.
Between 55% (in Germany) and 93% (in the United States) of PCPs have accessed the Internet, according to I.MD 2000, a global study conducted by Montreal-based P\S\L Research. Projections made based on stated future intentions indicate that by the second quarter of 2001, between 75% (in Germany and Italy) and 97% (in the United States) of primary care physicians will have accessed the Internet.
The international study was conducted through telephone calls with 1000 PCPs and an Internet-based study with roughly 750 PCPs who are confirmed Internet users.
According to P\S\L, however, knowing that a physician has ever used the Internet is only the first step in understanding how they are using it.
"Physicians are at various stages of development when it comes to using the Internet in their role as healthcare professionals," read a P\S\L statement. "For example, some physicians are using the Internet primarily to search for disease and drug information via general search engines, while others are referring regularly to specific Web sites, which provide a variety of medical information, tools and resources."
In addition to the role being played in seeking health-related information, communicating with other healthcare professionals and accessing various medical resources, the Internet is also playing a significant role in the relationship between the physician and his or her patient.
According to the study, between roughly 50% (in France, Italy and Spain) and 90% (in the United States) of online physicians are suggesting their patients use the Internet to obtain medical information. PR
Sanofi Bolsters Immunology Pipeline with Acquisition of Dren Bio’s DR-0201 for Up to $1.9 Billion
March 20th 2025DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.